HUP0104139A2 - 5-[{6-(2-fluor-benzil)-oxi-2-naftil}-metil]-2,4-tiazolidin-dion kristályok - Google Patents

5-[{6-(2-fluor-benzil)-oxi-2-naftil}-metil]-2,4-tiazolidin-dion kristályok

Info

Publication number
HUP0104139A2
HUP0104139A2 HU0104139A HUP0104139A HUP0104139A2 HU P0104139 A2 HUP0104139 A2 HU P0104139A2 HU 0104139 A HU0104139 A HU 0104139A HU P0104139 A HUP0104139 A HU P0104139A HU P0104139 A2 HUP0104139 A2 HU P0104139A2
Authority
HU
Hungary
Prior art keywords
crystal
oxy
naphthyl
methyl
thiazolidinedione
Prior art date
Application number
HU0104139A
Other languages
English (en)
Inventor
Akira Maruyama
Katsuhiko Masuda
Takayuki Oe
Hiroaki Ueno
Original Assignee
Mitsubishi Chemical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corporation filed Critical Mitsubishi Chemical Corporation
Publication of HUP0104139A2 publication Critical patent/HUP0104139A2/hu
Publication of HUP0104139A3 publication Critical patent/HUP0104139A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A találmány tárgya az 5-[{6-(2-fluor-benzil)-oxi-2-naftil}-metil]-2,4-tiazolidin-dion A típusú kristály, amely a por-röntgendiffrakciósgörbén 11,5°<0,3°, 14,5°<0,2°, 16,2°<0,3°, 17,0°<0,3°, 17,7°<0,2°,18,6°<0,3°, 19,1°<0,2°, 21,3°<0,4°, 22,4°<0,5°, 25,7°<0,5° és28,3°<0,5° értékeknél jellemző abszorpciós csúcsokkal (2Q)rendelkezik. A találmány tárgya továbbá a fenti vegyület A-kristály-típusának előállítási eljárása és a találmány szerinti vegyület A-kristály-típusát tartalmazó gyógyszerkészítmény. A találmány szerinti kristály kiváló stabilitással rendelkezik,előnyösen szállítható, tárolható és abból kiváló gyógyszerkészítményállítható elő. A találmány a fenti vegyület B-, C- és D-kristály-típusaira is vonatkozik. Ó
HU0104139A 1998-11-20 1999-11-19 Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione HUP0104139A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33054698 1998-11-20
PCT/JP1999/006492 WO2000031055A1 (en) 1998-11-20 1999-11-19 Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione

Publications (2)

Publication Number Publication Date
HUP0104139A2 true HUP0104139A2 (hu) 2002-03-28
HUP0104139A3 HUP0104139A3 (en) 2003-12-29

Family

ID=18233859

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104139A HUP0104139A3 (en) 1998-11-20 1999-11-19 Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione

Country Status (23)

Country Link
US (3) US6541493B1 (hu)
EP (1) EP1131310B1 (hu)
JP (1) JP3784001B2 (hu)
KR (1) KR100652326B1 (hu)
CN (1) CN1326449A (hu)
AT (1) ATE315552T1 (hu)
AU (1) AU1185100A (hu)
BR (1) BR9916795A (hu)
CA (1) CA2351727C (hu)
CZ (1) CZ20011763A3 (hu)
DE (1) DE69929476T2 (hu)
ES (1) ES2257104T3 (hu)
HU (1) HUP0104139A3 (hu)
ID (1) ID30064A (hu)
IL (1) IL143177A0 (hu)
NO (1) NO20012444L (hu)
NZ (1) NZ512429A (hu)
PL (1) PL348502A1 (hu)
PT (1) PT1131310E (hu)
TR (4) TR200202110T2 (hu)
TW (2) TWI250156B (hu)
WO (1) WO2000031055A1 (hu)
ZA (1) ZA200104081B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL348502A1 (en) * 1998-11-20 2002-05-20 Mitsubishi Chem Corp Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
WO2001036401A1 (en) * 1999-11-19 2001-05-25 Ortho-Mcneil Pharmaceutical, Inc. Solid state forms of 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione
WO2002080936A1 (en) * 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
WO2007049050A2 (en) * 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
BRPI0907463A2 (pt) * 2008-02-04 2019-09-24 Pfizer Ltd forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
JP4023697B2 (ja) 1996-11-14 2007-12-19 三菱化学株式会社 ナフタレン誘導体の製造方法
PL348502A1 (en) * 1998-11-20 2002-05-20 Mitsubishi Chem Corp Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione

Also Published As

Publication number Publication date
DE69929476D1 (de) 2006-04-06
TWI272944B (en) 2007-02-11
TR200202110T2 (tr) 2002-10-21
ES2257104T3 (es) 2006-07-16
BR9916795A (pt) 2002-04-09
JP3784001B2 (ja) 2006-06-07
TW200613291A (en) 2006-05-01
TR200101901T2 (tr) 2002-04-22
CZ20011763A3 (cs) 2001-10-17
EP1131310A1 (en) 2001-09-12
CA2351727C (en) 2008-09-23
KR100652326B1 (ko) 2006-11-29
NZ512429A (en) 2003-11-28
NO20012444L (no) 2001-07-18
JP2002530392A (ja) 2002-09-17
EP1131310B1 (en) 2006-01-11
WO2000031055A1 (en) 2000-06-02
KR20010101033A (ko) 2001-11-14
ID30064A (id) 2001-11-01
ZA200104081B (en) 2002-05-20
IL143177A0 (en) 2002-04-21
HUP0104139A3 (en) 2003-12-29
US20060149075A1 (en) 2006-07-06
CA2351727A1 (en) 2000-06-02
TR200202109T2 (tr) 2002-11-21
DE69929476T2 (de) 2006-09-14
AU1185100A (en) 2000-06-13
NO20012444D0 (no) 2001-05-18
PL348502A1 (en) 2002-05-20
CN1326449A (zh) 2001-12-12
TR200202103T2 (tr) 2002-11-21
ATE315552T1 (de) 2006-02-15
TWI250156B (en) 2006-03-01
US6541493B1 (en) 2003-04-01
US20030158241A1 (en) 2003-08-21
PT1131310E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
CA2074155A1 (en) Herbicidal 4-acyl-5-arylisoxazoles
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
ATE310494T1 (de) Subgingivales pulverstrahlen
HUP0102292A2 (hu) Szubsztituált dioxo-tiazolidin-származékok, eljárás előállításukra és gyógyszerészeti felhasználásuk
ZA974984B (en) New substituted thiazolidine-2,4-dione derivatives, processes for the obtaining thereof, and pharmaceutical compositions containing them.
HUP0104139A2 (hu) 5-[{6-(2-fluor-benzil)-oxi-2-naftil}-metil]-2,4-tiazolidin-dion kristályok
EA200000655A1 (ru) Гидрат соли малеиновой кислоты 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
TR26619A (tr) YENI BILESIKLER,BUNLARIN HAZIRLANMALARINA YÖNELIK ISLEMLER,BUNLARI ICEREN BILESIMLER VE BUNLARIN ZARARLI OT ÖLDüRüCüSü(HERBISIDAL) OLARAK KULLANI- MI.
EA200101101A1 (ru) Новый фармацевтический препарат
NL173265B (nl) Werkwijze voor het bereiden van tussenprodukten voor de vorming van 4,4&#39;-dicyaan-polyhalogeen-difenoxyalkanen en het omzetten van deze tussenprodukten in deze dicyaan-verbindingen.
ITTO930535A0 (it) Procedimento per la realizzazione di lamiere metalliche e/o ceramiche tramite sinterizzazione di polveri e prodotto relativo.
EA200101102A1 (ru) Новый фармацевтический препарат
WO2000003978A3 (de) 2,5-substituierte benzolsulfonylharnstoffe und -thioharnstoffe, v,rfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
NZ213756A (en) Anti-inflammatory compositions containing indomethacin or piroxicam and a 2-guanidino-4-(4-imidazolyl)thiazole
JPS5219105A (en) Nonoxidative sintering and forging method
JPS53112875A (en) 1-chlorocarbonylmethyl-3-(3,5-dichlorophenyl)hydantoin, its preparation and industrial bactericide containing the same
JPS5334773A (en) Benzothiazole derivatives and preventives remedies containing the same for coccidiosis
HUP9701587A2 (hu) 3-(Klór-difluor-metoxi)-fenil-etilidén-amino-oxi-metil-fenil-származékok, intermedierjeik, a vegyületeket hatóanyagként tartalmazó fungicid készítmények és alkalmazásuk
JPS5248693A (en) Synthesis of noncyclic c-nucleosides
Mangra Studies concerning the use of the quartz as a carrier at the barium ferrite presintering
Liang et al. Review of laser processing research and development
JPS5353662A (en) Preparation of aminopyridines
Pandey Thermal expansion of La sub 2 O sub 3 from 100 Degrees to 300 Degrees K by an X-ray method
Hermansson et al. Hot Isostatic Pressing of Silicon Carbide With no Sintering Agents
WANG MICROSTRUCTURE-PROPERTY RELATION FOR PZT CERAMICS.